124 related articles for article (PubMed ID: 20384543)
1. Emerging biotherapies for Sjögren's syndrome.
Tobón GJ; Saraux A; Pers JO; Youinou P
Expert Opin Emerg Drugs; 2010 Jun; 15(2):269-82. PubMed ID: 20384543
[TBL] [Abstract][Full Text] [Related]
2. B cell-targeted therapies in Sjögren's syndrome.
Tobón GJ; Pers JO; Youinou P; Saraux A
Autoimmun Rev; 2010 Feb; 9(4):224-8. PubMed ID: 19671451
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential for B-cell modulation in Sjögren's syndrome.
Mariette X
Rheum Dis Clin North Am; 2008 Nov; 34(4):1025-33, x. PubMed ID: 18984420
[TBL] [Abstract][Full Text] [Related]
4. The future of B cell-targeted therapies in Sjögren's syndrome.
Cornec D; Saraux A; Devauchelle-Pensec V; Clodic C; Pers JO
Immunotherapy; 2013 Jun; 5(6):639-46. PubMed ID: 23725286
[TBL] [Abstract][Full Text] [Related]
5. Rituximab therapy in primary Sjögren's syndrome.
Alcântara C; Gomes MJ; Ferreira C
Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
[TBL] [Abstract][Full Text] [Related]
6. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
[TBL] [Abstract][Full Text] [Related]
7. Biologic treatment in Sjögren's syndrome.
Sada PR; Isenberg D; Ciurtin C
Rheumatology (Oxford); 2015 Feb; 54(2):219-30. PubMed ID: 25342375
[TBL] [Abstract][Full Text] [Related]
8. Emerging biological therapies in primary Sjogren's syndrome.
Ramos-Casals M; Brito-Zerón P
Rheumatology (Oxford); 2007 Sep; 46(9):1389-96. PubMed ID: 17586555
[TBL] [Abstract][Full Text] [Related]
9. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
Abdulahad WH; Kroese FG; Vissink A; Bootsma H
J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852
[TBL] [Abstract][Full Text] [Related]
10. [B lymphocytes in Sjögren's syndrome].
Pers JO; Le Pottier L; Devauchelle V; Saraux A; Youinou P
Rev Med Interne; 2008 Dec; 29(12):1000-6. PubMed ID: 18403061
[TBL] [Abstract][Full Text] [Related]
11. Advances in the diagnosis and concept of Sjögren's syndrome (autoimmune exocrinopathy).
Strand V; Talal N
Bull Rheum Dis; 1979-1980; 30(9):1046-52. PubMed ID: 398729
[No Abstract] [Full Text] [Related]
12. Pathogenesis of Sjögren's syndrome and therapeutic consequences.
Mariette X; Gottenberg JE
Curr Opin Rheumatol; 2010 Sep; 22(5):471-7. PubMed ID: 20671520
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy.
Fox PC
Ann N Y Acad Sci; 2007 Mar; 1098():15-21. PubMed ID: 17332090
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
[TBL] [Abstract][Full Text] [Related]
15. Immunoregulation in Sjögren's syndrome: influence of serum factors on T-cell subpopulations.
Moutsopoulos HM; Fauci AS
J Clin Invest; 1980 Feb; 65(2):519-28. PubMed ID: 6444308
[TBL] [Abstract][Full Text] [Related]
16. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
Guzman Moreno R
Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
[TBL] [Abstract][Full Text] [Related]
17. Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias.
Tzioufas AG; Voulgarelis M
Best Pract Res Clin Rheumatol; 2007 Dec; 21(6):989-1010. PubMed ID: 18068857
[TBL] [Abstract][Full Text] [Related]
18. Transfer of Sjögren's syndrome-like autoimmune lesions into SCID mice and prevention of lesions by anti-CD4 and anti-T cell receptor antibody treatment.
Hayashi Y; Haneji N; Hamano H; Yanagi K
Eur J Immunol; 1994 Nov; 24(11):2826-31. PubMed ID: 7957574
[TBL] [Abstract][Full Text] [Related]
19. An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren's syndrome.
Mackay F; Groom JR; Tangye SG
Curr Opin Rheumatol; 2007 Sep; 19(5):406-13. PubMed ID: 17762603
[TBL] [Abstract][Full Text] [Related]
20. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
Saraux A
Autoimmun Rev; 2010 Jul; 9(9):609-14. PubMed ID: 20452466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
